nach oben

International Urology and Nephrology

Erschienen in:

02.08.2017 | Urology - Original Paper

Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery

verfasst von: Sheng-Fu Chen, Yuan-Hong Jiang, Hann-Chorng Kuo

Erschienen in: International Urology and Nephrology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Detrusor underactivity (DU) is frequently encountered in elderly patients. Part of patients with DU might have bladder function recovery after treatment. This study investigated urinary proteins in these DU patients with and without bladder function recovery.

Methods

A total of 37 patients with chronic urinary retention and urodynamically proven DU were enrolled. After treatment, 24 DU patients had bladder function recovery whereas 13 had not, after 1-year follow-up. Urine collection at baseline was performed, and the urinary protein including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and prostaglandin E2 (PGE2) were measured by ELISA. Twenty urodynamically normal, 34 detrusor overactivity (DO) and 15 detrusor hyperactivity and inadequate contractility (DHIC) patients served as comparative groups.

Results

Urinary NGF levels were significantly higher than normal in patients with DU (9.2 ± 20.3 vs 1.85 ± 2.9 pg/ml, p = 0.037). Urinary BDNF level was only significantly higher in patients with DU than that of the control group (153 ± 199 vs 77.4 ± 47.7 pg/ml, p = 0.033) but not in patients with DHIC or DO. Compared with the control group, the urinary BDNF level was significantly higher in DU patients with bladder function recovery (190 ± 239 pg/ml, p = 0.033) but not in patients without recovery (85.8 ± 43.7 pg/ml, p = 0.612). The PGE2 level was significantly higher than the control group in DU patients with bladder function recovery (1290 ± 836 pg/ml, p < 0.0001) but not in patients without recovery (383 ± 237 pg/ml, p = 0.130).

Conclusion

Patients with DU and higher urinary PGE2 and BDNF levels might have a chance to recover bladder function than those with a lower protein level.

Andersson KE (2014) The many faces of impaired bladder emptying. Curr Opin Urol 24:363–369CrossRefPubMed

Smith PP (2010) Aging and the underactive detrusor: a failure of activity or activation? Neurourol Urodyn 29:408–412PubMed

Kanai A, Andersson KE (2010) Bladder afferent signaling: recent findings. J Urol 183:1288–1295CrossRefPubMedPubMedCentral

Resnick NM, Yalla SV, Laurino E (1989) The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med 320:1–7CrossRefPubMed

Sakakibara R et al (2005) Is lumbar spondylosis a cause of urinary retention in elderly women? J Neurol 252:953–957CrossRefPubMed

Pizzi A et al (2014) Urinary incontinence after ischemic stroke: clinical and urodynamic studies. Neurourol Urodyn 33:420–425CrossRefPubMed

Ueda T, Yoshimura N, Yoshida O (1997) Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response. J Urol 157:590–594CrossRef

Andersson KE (2010) Detrusor underactivity/underactive bladder: new research initiatives needed. J Urol 184:1829–1830CrossRefPubMed

Miyazato M, Yoshimura N, Chancellor MB (2013) The other bladder syndrome: underactive bladder. Rev Urol 15:11–22PubMedPubMedCentral

10.

Van Koeveringe GA, Vahabi B, Andersson KE, Kirschner-Herrmans R, Oelke M (2011) Detrusor underactivity: a plea for new approaches to a common bladder dysfunction. Neurourol Urodyn 30:723–728CrossRefPubMed

11.

Chancellor MB, Blaivas JG (1995) Classification of neurogenic bladder disease. In: Chancellor MB (ed) Practical Neurourology. Butterworth. Heinemann, Boston, pp 25–32

12.

Steers WD, Tuttle JB (2006) Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 3:101–110CrossRefPubMed

13.

Kim JC, Park EY, Seo SI, Park YH, Hwang TK (2006) Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 175:1773–1776CrossRefPubMed

14.

Kuo HC (2012) Potential biomarkers utilized to define and manage overactive bladder syndrome. LUTS 1:32–41

15.

Antunes-Lopes T et al (2013) Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol 189:359–365CrossRefPubMed

16.

Wang LW, Han XM, Chen CH, Ma Y, Hai B (2014) Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. Int Urol Nephrol 46:341–347CrossRefPubMed

17.

Cruz CD (2014) neurotrophins in bladder function: what do we know and where do we go from here? Neurourol Urodyn 3:39–45CrossRef

18.

Richter HE et al (2017) Urinary biomarkers in women with refractory urgency urinary incontinence randomized to sacral neuromodulation versus onabotulinumtoxinA compared to controls. J Urol 197:1487–1495CrossRefPubMed

19.

Abrams P et al (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 187:116–126CrossRefPubMed

20.

Alkis O, Zumrutbas AE, Toktas C, Aybek H, Aybek Z (2017) The use of biomarkers in the diagnosis and treatment of overactive bladder: can we predict the patients who will be resistant to treatment? Neurourol Urodyn 36:390–393CrossRefPubMed

21.

Cho KJ, Kim HS, Koh JS, Kim JC (2013) Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics. Int Urogynecol J 24:325–330CrossRefPubMed

22.

Fry CH, Sahai A, Vahabi B, Kanai AJ, Birder LA (2014) What s the role for biomarkers for lower urinary tract disorders. Neurourol Urodyn 33:602–605CrossRefPubMedPubMedCentral

23.

Yamauchi H, Akino H, Ito H, Aoki Y, Nomura T, Yokoyama O (2010) Urinary prostaglandin E2 was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome. Urology 76:1267.e13–1267.e19CrossRef

24.

Ochodnicky P, Cruz CD, Yoshimura N, Cruz F (2012) Neurotrophins as regulators of urinary bladder function. Nat Rev Urol 9:628–637PubMed

25.

Andersson KE, Arner A (2004) Urnary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 84:935–986CrossRefPubMed

26.

McCafferty GP, Misajet BA, Laping NJ, Edwards RM, Thorneloe KS (2008) Enhanced bladder capacity and reduced prostaglandin E2-mediated bladder hyperactivity in EP3 receptor knockout mice. Am J Physiol Renal Physiol 295:F507–514CrossRefPubMed

27.

Shioyama R et al (2008) Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat. Am J Physiol Regul Integr Comp Physiol 295:R714–718CrossRefPubMed

28.

Aoki K et al (2009) A higher level of prostaglandin E2 in the urinary bladder in young boys and boys with lower urinary tract obstruction. Biomed Res 30:343–347CrossRefPubMed

29.

Kim JC et al (2005) Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder syndrome. Int J Urol 12:875–880CrossRefPubMed

30.

Yokoyama O et al (2011) Antimuscarinics suppress adenosine triphosphate and prostaglandin E2 release from urthelium with potential improvement in detrusor overactivity in rats with cerebral infarction. J Urol 185:2392–2397CrossRefPubMed

31.

Kuga N, Tanioka A, Hagihara K, Kawai T (2016) Moulation of afferent nerve activity by prostaglandin E2 upon urinary bladder distension in rats. Exp Physiol 10:577–587CrossRef

32.

Guan NN, Nilsson KF, Wiklund PN, Gustafsson LE (2014) Release and inhibitory effects of prostaglandin D2 in guinea pig urinary bladder and the role of urothelium. Biochim Biophys Acta 1840:3443–3451CrossRefPubMed

33.

Hindley R, Brierly RD, Thomas PJ (2004) Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity. BJU Int 93:89–92CrossRefPubMed

34.

Birder LA et al (2012) How does the urothelium affect bladder function in health and diseases? ICI-RS 2011. Neurourol Urodyn 31:293–299CrossRefPubMedPubMedCentral

35.

Birder LA et al (2001) Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci USA 98:13396–13401CrossRefPubMedPubMedCentral

36.

Downie JW, Karmazny M (1984) Mechanical trauma to bladder epithelium liberates prostanoids which modulate neurotransmission in rabbit detrusor muscle. J Pharmacol Exp Ther 230:445–449PubMed

37.

Andersson KE (2002) Bladder activation: afferent mechanisms. Urology 59:43–50CrossRefPubMed

38.

Sui GP, Wu C, Roosen A, Ikeda Y, Kanai AJ, Fry CH (2008) Modulation of bladder myofibroblast activity: implications for bladder function. Am J Physiol 295:F688–697

39.

Jiang YH, Wang CC, Kuo HC (2017) Urothelial barrier deficits, suburothelial inflammation and altered sensory protein expression in detrusor underactivity. J Urol 197:197–203CrossRefPubMed

40.

Cartwright R, Afshan I, Derpapas A, Vijaya G, Khullar V (2011) Novel biomarkers for overactive bladder. Nat Rev Urol 8:139–145CrossRefPubMed

41.

Gamper M, Moser R, Viereck V (2017) Have we been led astray by the NGF biomarker data? Neurourol Urodyn 36:203–204CrossRefPubMed

Titel: Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery
verfasst von: Sheng-Fu Chen
Yuan-Hong Jiang
Hann-Chorng Kuo
Publikationsdatum: 02.08.2017
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 10/2017
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-017-1666-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2017

Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis

Elderly patients with chronic kidney disease have higher risk of hyperparathyroidism

Smoking as a risk factor for diabetic nephropathy: a meta-analysis

Factors affecting responsiveness to hepatitis B immunization in dialysis patients

Thymoma-associated renal pathology: Is renal biopsy always necessary? A clinical problem-solving exercise and teaching example for physicians